Biotechnology News and Research

RSS

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

Cytometry system to precisely control cell movement using sound waves

Applied Biosystems, part of Life Technologies Corporation today announced its entry into the flow cytometry instrumentation market with the debut of the Attune™ Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells.

7 Dec 2009

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Seattle Genetics, Inc. today reported data from a phase I weekly-dosing clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), including multiple complete and partial remissions in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL).

7 Dec 2009

New study reveals RNA may play a critical role in cancer treatment

Researchers from Yale University and Mirna Therapeutics, Inc., reversed the growth of lung tumors in mice using a naturally occurring tumor suppressor microRNA. The study reveals that a tiny bit of RNA may one day play a big role in cancer treatment, and provides hope for future patients battling one of the most prevalent and difficult to treat cancers.

7 Dec 2009

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.

7 Dec 2009

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

7 Dec 2009

WuXi PharmaTech purchases Labcyte POD 810 plate assembler

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today it has purchased a Labcyte POD(TM) 810 plate assembler equipped with an Echo(R) 555 acoustic liquid handler for its work in high- throughput screening and secondary screening.

7 Dec 2009

China life science companies receive 'Most Promising Company' awards

The 7th ChinaBio® Investor Forum, held December 2-3, 2009 in Tianjin, concluded a successful meeting by giving “Most Promising Company” awards to two young China life science companies.

7 Dec 2009

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).

7 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Vivakor's shareholders to receive stock dividend of HealthAmerica

Vivakor, Inc. (OTC Bulletin Board: VIVK) today confirmed that its shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors.

5 Dec 2009

Vertex Pharmaceuticals reports underwriters purchase additional stock at 38.50 per share

Vertex Pharmaceuticals Incorporated today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per share.

5 Dec 2009

Biotechnology Consulting Poland applies to the EU for structural and cohesion funding

In the same way that the European Union has previously made major infrastructure investments in countries such as Ireland, the EU is now encouraging and funding the development of high tech companies in Poland through its Structural and Cohesion Funds.

5 Dec 2009

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection provides the following recap of yesterday's investor conference call, which discussed the Company’s acquisition of intellectual property rights from Los Alamos National Security.

5 Dec 2009

Licensing agreement to develop and commercialize potential treatment for Gaucher’s disease signed

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Protalix (NYSE-Amex: PLX), a leading biopharmaceutical company, in its licensing agreement with Pfizer Inc. to develop and commercialize a potential treatment for Gaucher’s disease, a genetic disorder.

5 Dec 2009

Health experts available to speak about health care reform

Garson helped originate and draft the "Health Partnership Act" (S. 325 and H.R. 5606), which funds grants to states for innovations to improve coverage for the uninsured, quality and efficiency.

5 Dec 2009

DOE and USDA announce $600 million grants and loan guarantees to build new biorefinery projects

The Biotechnology Industry Organization (BIO) today applauded the announcement of over $600 million in grants and loan guarantees to help build 19 new biorefinery projects to produce advanced biofuels and biobased chemicals from renewable feedstocks. The funding represents the largest single federal investment in advanced biorefineries to date.

5 Dec 2009

Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science

Fluxion Biosciences announced today that it has expanded its sales and service network into Asia. The company signed a distribution agreement for its BioFlux™ line with Korea-based DI Biotech. A second agreement with Novel Science covers sales of both the BioFlux and IonFlux™ platforms in Japan. Fluxion has also sold its first BioFlux 1000 system into China.

From Fluxion Biosciences 4 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

ICON receives FDA warning letter

ICON plc,, today announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006.

4 Dec 2009

Biotechnology News and Research

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Cytometry system to precisely control cell movement using sound waves

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

New study reveals RNA may play a critical role in cancer treatment

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

WuXi PharmaTech purchases Labcyte POD 810 plate assembler

China life science companies receive 'Most Promising Company' awards

Amgen announces results from three studies on the safety and efficacy of Nplate

Stem cell treatment: A new hope for Multiple Sclerosis

Vivakor's shareholders to receive stock dividend of HealthAmerica

Vertex Pharmaceuticals reports underwriters purchase additional stock at 38.50 per share

Biotechnology Consulting Poland applies to the EU for structural and cohesion funding

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Licensing agreement to develop and commercialize potential treatment for Gaucher’s disease signed

Health experts available to speak about health care reform

DOE and USDA announce $600 million grants and loan guarantees to build new biorefinery projects

Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

ICON receives FDA warning letter

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News